{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:18Z","timestamp":1707524478969},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,18]]},"DOI":"10.7759\/cureus.19699","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T14:13:50Z","timestamp":1637244830000},"source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Diffuse Large B-Cell Non-Hodgkin\u2019s Lymphoma After Gemcitabine-Based Second Salvage Chemotherapy: A Single-Center Study"],"prefix":"10.7759","author":[{"given":"Mussadique Ali","family":"Jhatial","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manzoor","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saif ur","family":"Rab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naila","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandumal","family":"Loohana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed W","family":"Imam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151","article-title":"2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar-Adaniya S","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021, 96:617-29. 10.1002\/ajh.26151","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3237","article-title":"Recent survival trends in diffuse large B-cell lymphoma--have we made any progress beyond rituximab?","volume":"9","author":"Epperla N","year":"2020","unstructured":"Epperla N, Vaughn JL, Othus M, Hallack A, Costa LJ. Recent survival trends in diffuse large B-cell lymphoma--have we made any progress beyond rituximab?. Cancer Med. 2020, 9:5519-25. 10.1002\/cam4.3237","journal-title":"Cancer Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump M","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al.. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017, 130:1800-8. 10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher RI","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al.. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993, 328:1002-6.","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier B","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346:235-42. 10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann TM","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, et al.. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006, 24:3121-7. 10.1200\/JCO.2005.05.1003","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh M","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, et al.. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011, 12:1013-22. 10.1016\/S1470-2045(11)70235-2","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn LH","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, et al.. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007, 109:1857-61. 10.1182\/blood-2006-08-038257","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/2278-330X.126531","article-title":"Management of relapsed-refractory diffuse large B cell lymphoma","volume":"3","author":"Raut LS","year":"2014","unstructured":"Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer. 2014, 3:66-70. 10.4103\/2278-330X.126531","journal-title":"South Asian J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/9.suppl_1.s9","article-title":"High-dose therapy for diffuse large-cell lymphoma in first remission","volume":"1","author":"Perry AR","year":"19989","unstructured":"Perry AR, Goldstone AH. High-dose therapy for diffuse large-cell lymphoma in first remission. Ann Oncol. 19989, 1:9-14. 10.1093\/annonc\/9.suppl_1.s9","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh M","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Osterborg A, et al.. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006, 7:379-91. 10.1016\/S1470-2045(06)70664-7","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/2.suppl_1.57","article-title":"PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)","volume":"2 Suppl 1","author":"Philip T","year":"1991","unstructured":"Philip T, Chauvin F, Bron D, et al.. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann Oncol. 1991, 2 Suppl 1:57-64. 10.1093\/annonc\/2.suppl_1.57","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05603.x","article-title":"Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens","volume":"130","author":"Ardeshna KM","year":"2005","unstructured":"Ardeshna KM, Kakouros N, Qian W, et al.. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol. 2005, 130:363-72. 10.1111\/j.1365-2141.2005.05603.x","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip T","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, et al.. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995, 333:1540-5. 10.1056\/NEJM199512073332305","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez WS","year":"1994","unstructured":"Velasquez WS, McLaughlin P, Tucker S, et al.. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994, 12:1169-76. 10.1200\/JCO.1994.12.6.1169","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma","volume":"17","author":"Moskowitz CH","year":"1999","unstructured":"Moskowitz CH, Bertino JR, Glassman JR, et al.. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999, 17:3776-85. 10.1200\/JCO.1999.17.12.3776","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008294725992","article-title":"Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation","volume":"8","author":"Girouard C","year":"1997","unstructured":"Girouard C, Dufresne J, Imrie K, et al.. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol. 1997, 8:675-80. 10.1023\/a:1008294725992","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.06.036","article-title":"Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation","volume":"20","author":"Hamadani M","year":"2014","unstructured":"Hamadani M, Hari PN, Zhang Y, et al.. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014, 20:1729-36. 10.1016\/j.bbmt.2014.06.036","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.8.2142.2142","article-title":"Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up","volume":"80","author":"Vose JM","year":"1992","unstructured":"Vose JM, Bierman PJ, Anderson JR, et al.. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood. 1992, 80:2142-8. 10.1182\/blood.V80.8.2142.2142","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste E","year":"2016","unstructured":"Van Den Neste E, Schmitz N, Mounier N, et al.. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016, 51:51-7. 10.1038\/bmt.2015.213","journal-title":"Bone Marrow Transplant"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1179\/102453308X343527","article-title":"Utility of subsequent conventional dose chemotherapy in relapsed\/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy","volume":"13","author":"Seshadri T","year":"2008","unstructured":"Seshadri T, Stakiw J, Pintilie M, Keating A, Crump M, Kuruvilla J. Utility of subsequent conventional dose chemotherapy in relapsed\/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy. Hematology. 2008, 13:261-6. 10.1179\/102453308X343527","journal-title":"Hematology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer JN","year":"2013","unstructured":"Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013, 10:267-76. 10.1038\/nrclinonc.2013.46","journal-title":"Nat Rev Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7150\/jca.36997","article-title":"Prognostic nomogram and predictive factors in refractory or relapsed diffuse large B-cell lymphoma patients failing front-line R-CHOP regimens","volume":"11","author":"Jiang S","year":"2020","unstructured":"Jiang S, Qin Y, Liu P, et al.. Prognostic nomogram and predictive factors in refractory or relapsed diffuse large B-cell lymphoma patients failing front-line R-CHOP regimens. J Cancer. 2020, 11:1516-24. 10.7150\/jca.36997","journal-title":"J Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/107327481201900305","article-title":"Diffuse large B-cell lymphoma: current strategies and future directions","volume":"19","author":"Cultrera JL","year":"2012","unstructured":"Cultrera JL, Dalia SM. Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control. 2012, 19:204-13. 10.1177\/107327481201900305","journal-title":"Cancer Control"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht C","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, et al.. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010, 28:4184-90. 10.1200\/JCO.2010.28.1618","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000489717","article-title":"R-ICE chemotherapy with or without autologous transplantation for elderly patients with relapsed or refractory aggressive B-cell lymphomas","volume":"41","author":"Turki AT","year":"2018","unstructured":"Turki AT, Lamm W, Liebregts T, D\u00fchrsen U. R-ICE chemotherapy with or without autologous transplantation for elderly patients with relapsed or refractory aggressive B-cell lymphomas. Oncol Res Treat. 2018, 41:534-8. 10.1159\/000489717","journal-title":"Oncol Res Treat"},{"key":"ref28","article-title":"Effect of second-line chemotherapy in treating relapsed or refractory diffuse large B cell lymphoma and prognosis analysis","volume":"25","author":"Wang S","year":"2020","unstructured":"Wang S, Bai Y. Effect of second-line chemotherapy in treating relapsed or refractory diffuse large B cell lymphoma and prognosis analysis. J BUON. 2020, 25:2003-10.","journal-title":"J BUON"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.11.008","article-title":"Outcomes of transplant-eligible patients with relapsed or refractory diffuse large b-cell lymphoma after second-line salvage chemotherapy: the Gustave Roussy experience","volume":"21","author":"Rassy E","year":"2021","unstructured":"Rassy E, Danu A, Ibrahim T, et al.. Outcomes of transplant-eligible patients with relapsed or refractory diffuse large b-cell lymphoma after second-line salvage chemotherapy: the Gustave Roussy experience. Clin Lymphoma Myeloma Leuk. 2021, 21:e373-80. 10.1016\/j.clml.2020.11.008","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/75500-outcomes-of-diffuse-large-b-cell-non-hodgkins-lymphoma-after-gemcitabine-based-second-salvage-chemotherapy-a-single-center-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:57Z","timestamp":1707506997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/75500-outcomes-of-diffuse-large-b-cell-non-hodgkins-lymphoma-after-gemcitabine-based-second-salvage-chemotherapy-a-single-center-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.19699","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,18]]}}}